[Research Progress of Antibody-conjugated Drugs in Non-small Cell Lung Cancer]
Abstract:
Lung cancer is the most common malignant tumor and the second most common malignant tumor in terms of mortality in the world. Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. Currently, the first-line standard treatment for advanced NSCLC is immunotherapy and targeted therapy. Although these treatments prolong the survival of patients, acquired drug resistance is still inevitable. Antibody-drug conjugates (ADCs) are a new type of anti-tumor drug made by coupling cytotoxic payloads to specific monoclonal antibodies via linkers. Compared with chemotherapy drugs, ADCs have the advantages of accurate recognition, local release, and high patient tolerance. In recent years, they have shown good clinical benefits in the treatment of NSCLC. This article provides an overview of the mechanism of action of ADCs, clinical studies progress in advanced NSCLC, and existing problems and challenges. .
Insights
Antibody-drug conjugates (ADCs) offer a promising new treatment for non-small cell lung cancer (NSCLC). These targeted therapies show clinical benefits, overcoming resistance issues common with current advanced NSCLC treatments.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Lung cancer is a leading cause of cancer mortality worldwide, with non-small cell lung cancer (NSCLC) being the most prevalent type.
- Current first-line treatments for advanced NSCLC, including immunotherapy and targeted therapy, face challenges with acquired drug resistance.
- Antibody-drug conjugates (ADCs) represent an emerging therapeutic class for cancer treatment.
Purpose of the Study:
- To provide an overview of the mechanism of action of Antibody-drug conjugates (ADCs).
- To review the clinical progress of ADCs in treating advanced non-small cell lung cancer (NSCLC).
- To discuss the current challenges and future directions for ADC therapy in NSCLC.
Main Methods:
- Review of existing literature on Antibody-drug conjugates (ADCs) in oncology.
- Analysis of clinical trial data and outcomes for ADCs in advanced non-small cell lung cancer (NSCLC).
- Synthesis of information regarding ADC mechanisms, efficacy, and limitations.
Main Results:
- ADCs demonstrate targeted delivery of cytotoxic payloads, enhancing anti-tumor activity and patient tolerance compared to traditional chemotherapy.
- Recent clinical studies show significant benefits and promising survival outcomes for ADCs in advanced NSCLC.
- ADCs have shown efficacy in overcoming acquired resistance to prior therapies.
Conclusions:
- Antibody-drug conjugates (ADCs) are a significant advancement in the treatment of advanced non-small cell lung cancer (NSCLC).
- Further research and development are needed to address existing challenges and optimize ADC therapy for broader patient populations.
- ADCs hold considerable potential to improve outcomes for patients with advanced NSCLC.
